Search results for " VAS"

showing 10 items of 1524 documents

Endothelium-dependent relaxation of human saphenous veins in response to vasopressin and desmopressin

1997

Purpose: The goal of this study was to determine the effects of vasopressin and the selective V 2 -receptor agonist desmopressin on human saphenous veins, with special emphasis on endothelium-mediated responses. Methods: Human saphenous vein segments were obtained from 35 patients undergoing coronary bypass surgery. Paired segments, one normal and the other deendothelized by gentle rubbing, were mounted for isometric recording of tension in organ baths. Concentration-response curves to vasopressin and desmopressin were determined in the presence and in the absence of either the V,-receptor antagonist d(CH 2 ) 5 Tyr(Me)AVP (10 −6 mol/L), the V 1 -V 2 receptor antagonist desGly-d(CH 2 ) 5 D-T…

AdultMaleAgonistReceptors Vasopressinmedicine.medical_specialtyVasopressinVasopressinsmedicine.drug_classVasodilator AgentsIndomethacinVasodilationHormone AntagonistsVasotocinIsometric ContractionInternal medicinemedicineHumansVasoconstrictor AgentsCyclooxygenase InhibitorsDeamino Arginine VasopressinSaphenous VeinEnzyme InhibitorsDesmopressinReceptorAgedDose-Response Relationship Drugbusiness.industryAntagonistMiddle AgedReceptor antagonistArginine VasopressinNG-Nitroarginine Methyl EsterEndocrinologyProstaglandinsFemaleSurgeryEndothelium VascularNitric Oxide Synthasemedicine.symptombusinessCardiology and Cardiovascular MedicineAntidiuretic Hormone Receptor AntagonistsVasoconstrictionhormones hormone substitutes and hormone antagonistsmedicine.drugJournal of Vascular Surgery
researchProduct

Prevalence of Apolipoprotein E Alleles in Healthy Subjects and Survivors of Ischemic Stroke

1998

Background and Purpose —The ε4 allele of the apolipoprotein E (apoE) has been related to the occurrence of myocardial infarction, but its association with ischemic stroke is controversial. We have evaluated the relation between apoE alleles and the occurrence of cerebrovascular ischemia. Methods —The apoE ε genotypes of 100 patients with a documented history of ischemic stroke without clinically apparent dementia (stroke+) and 108 subjects without such history (stroke−) were determined. The relative frequency of the apoE alleles and genotypes was estimated in 398 healthy subjects aged <40 years from the same ethnic background. Results —The frequency of the apoE ε4 allele in stroke+ (0.1…

AdultMaleApolipoprotein Emedicine.medical_specialtyGastroenterologyBrain IschemiaCentral nervous system diseaseApolipoproteins EReference ValuesRisk FactorsInternal medicineOdds RatiomedicineHumansSurvivorsMyocardial infarctionRisk factorAlleleStrokeAllelesAgedAged 80 and overAdvanced and Specialized Nursingbusiness.industryDementia VascularHomozygoteCase-control studyMiddle Agedmedicine.diseaseThrombosisSurgeryItalyCase-Control StudiesFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessStroke
researchProduct

Non invasive evaluation of endothelial function in patients with Anderson-Fabry disease.

2005

AIM: Fabry's disease is an X-linked recessive abnormality of glycosphingolipid metabolism. Increased levels of endothelial prothrombotic factors have recently been demonstrated in Fabry's disease, whereas endothelial function has not been studied using high resolution ultrasound. METHODS: We enrolled 6 patients (4 male, 2 female; mean age, 37 years) and 12 sex matched control subjects (mean age, 37 years). Patients' exclusion criteria included a prior history of cardiac disease, diabetes and treated or untreated hypertension. Patients underwent: anamnesis, physical examination, EKG, 2-dimensional echocardiography with tissue Doppler, measurement of body weight and height, blood pressure. Bi…

AdultMaleBrachial ArteryFabry's diseaseHyperemiaMiddle Agedendothelial dysfunctionVasodilationElectrocardiographyC-Reactive Proteincardiovascular diseaseRegional Blood Flowrisk factorsFabry DiseaseHumansFemaleEndothelium VascularUltrasonographyInternational angiology : a journal of the International Union of Angiology
researchProduct

Effect of acute systemic hypoxia on human cutaneous microcirculation and endothelial, sympathetic and myogenic activity

2015

The regulation of cutaneous vascular tone impacts vascular vasomotion and blood volume distribution as a challenge to hypoxia, but the regulatory mechanisms yet remain poorly understood. A skin has a very compliant circulation, an increase in skin blood flow results in large peripheral displacement of blood volume, which could be controlled by local and systemic regulatory factors. The aim of this study was to determine the acute systemic hypoxia influence on blood flow in skin, local regulatory mechanism fluctuations and changes of systemic hemodynamic parameters. Healthy subjects (n=11; 24.9±3.7years old) participated in this study and procedures were performed in siting position. After 2…

AdultMaleCardiac outputSympathetic Nervous SystemHemodynamicsBlood volumeVasomotionVasodilationBiochemistryYoung AdultHeart RateHumansMedicineCardiac OutputHypoxiaSkinbusiness.industryMicrocirculationCell BiologyBlood flowHypoxia (medical)VasodilationBlood pressureRegional Blood FlowAnesthesiaAcute DiseaseFemaleEndothelium Vascularmedicine.symptomCardiology and Cardiovascular MedicinebusinessMicrovascular Research
researchProduct

Rosuvastatin Prevents Conduit Artery Endothelial Dysfunction Induced by Ischemia and Reperfusion by a Cyclooxygenase-2–Dependent Mechanism

2010

ObjectivesThe purpose of this study was to determine whether single-dose rosuvastatin (40 mg) protects against ischemia and reperfusion (IR)–induced endothelial dysfunction in humans and whether this effect is cyclooxygenase (COX)-2 dependent.BackgroundAnimal studies have demonstrated that rosuvastatin can limit damage and improve recovery after IR.MethodsIn a double-blind, parallel design, 20 volunteers were randomized to a single dose of oral rosuvastatin (40 mg) or placebo. Twenty-four hours later, endothelium-dependent, flow-mediated dilation (FMD) of the radial artery was measured before and after IR (15 min of upper arm ischemia followed by 15 min of reperfusion). In a separate protoc…

AdultMaleEndotheliumendotheliumAdolescentPremedicationIschemiaMyocardial Reperfusion InjuryPharmacologyPlaceboYoung AdultDouble-Blind Methodmedicineischemia reperfusionHumansRosuvastatinEndothelial dysfunctionRosuvastatin CalciumSulfonamidesCyclooxygenase 2 Inhibitorsbusiness.industryModels Cardiovascularnutritional and metabolic diseases3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitormedicine.diseaseFluorobenzenesVasodilationRosuvastatin Calciummedicine.anatomical_structurePyrimidinesCelecoxibCyclooxygenase 2AnesthesiaIschemic Preconditioning MyocardialRadial ArteryCelecoxibIschemic preconditioningPyrazolesFemaleEndothelium VascularHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCardiology and Cardiovascular Medicinerosuvastatinmedicine.drugJournal of the American College of Cardiology
researchProduct

Desmopressin in the Treatment of Nocturia: A Double-Blind, Placebo-Controlled Study

2007

Objectives: To investigate efficacy, safety, and impact on quality of sleep of desmopressin in the treatment of nocturia. Methods: Adults aged >= 18 yr with nocturia (>= 2 voids/night) received desmopressin tablets (0.1, 0.2, or 0.4 mg) during a 3-wk dose-titration period. Patients should show sufficient response during the dose-titration period (>= 20% reduction in nocturnal diuresis) and a return of nocturnal diuresis to >= 80% of baseline levels during washout. Eligible patients then entered a 3-wk double-blind treatment period and received either desmopressin or placebo. Results: 127 patients were randomised to either desmopressin (n = 61) or placebo (n = 66). Twenty (33%) desmopressin-…

AdultMaleNephrologymedicine.medical_specialtyUrologyPlacebo-controlled studyAdministration OralDiuresisPlaceboDouble-Blind MethodInternal medicinemedicineHumansNocturiaDeamino Arginine VasopressinDesmopressinAdverse effectAgedAged 80 and overDose-Response Relationship Drugbusiness.industryAntidiuretic AgentsMiddle AgedSurgeryUrodynamicsTreatment OutcomeAnesthesiaFemaleNocturiamedicine.symptomSleepbusinesshormones hormone substitutes and hormone antagonistsFollow-Up Studiesmedicine.drugAntidiureticEuropean Urology
researchProduct

Enhancement of endothelial cell E-selectin expression by sera from patients with active Behçet's disease: moderate correlation with anti-endothelial …

1999

We studied the in vitro E-selection expression of endothelial cells treated with sera from patients with Behcet's disease (BD) and factors (anti-endothelial cell antibodies, anti-neutrophil cytoplasmic antibodies, cytokines, and myeloperoxidase (MPO) that may contribute to adhesion molecule expression. A total of 21 patients with BD and 27 healthy controls were studied. In vitro E-selectin endothelial cell expression was investigated by ELISA after HUVEC incubation with sera or purified IgG from patients with BD and controls. Increased E-selectin expression was observed when endothelial cells were incubated with sera from patients with active disease or from patients with circulating anti-e…

AdultMaleNeutrophilsImmunologyCellIn Vitro TechniquesImmunoglobulin GAntibodies Antineutrophil CytoplasmicE-selectinmedicineImmunology and AllergyHumansCells CulturedAgedAutoantibodiesPeroxidasebiologyCell adhesion moleculeBehcet SyndromeAutoantibodyMiddle AgedMolecular biologyEndothelial stem cellmedicine.anatomical_structureMyeloperoxidaseImmunoglobulin GImmunologybiology.proteinCytokinesFemaleEndothelium VascularAntibodyE-SelectinClinical immunology (Orlando, Fla.)
researchProduct

Efficacy and Safety of Cetuximab/Irinotecan in Chemotherapy-Refractory Metastatic Colorectal Adenocarcinomas: A Clinical Practice Setting, Multicente…

2006

This study was designed to evaluate the efficacy and safety of irinotecan/cetuximab administered as third- or fourth-line therapy in a retrospective series of patients with metastatic colorectal cancer refractory to oxaliplatin and irinotecan. Patients and Methods: Most patients (90%) had been previously treated with adjuvant 5-fluorouracil/leucovorin, and all had received oxaliplatin-based regimens before receiving irinotecan- based second-line treatment. Sixty patients with irinotecan-refractory colorectal cancer received a regimen comprising weekly irinotecan 120 mg/m 2 as a 1-hour intravenous infusion and cetuximab 400 mg/m 2 infused over 2 hours as the initial dose and 250 mg/m 2 infus…

AdultMaleOncologymedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsSettore MED/06 - Oncologia MedicaColorectal cancermedicine.medical_treatmentCetuximabAdenocarcinomaAntibodies Monoclonal HumanizedIrinotecanDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisSurvival analysisAgedAged 80 and overChemotherapyCetuximabPerformance statusbusiness.industryGastroenterologyAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesOxaliplatinErbB ReceptorsIrinotecanSettore MED/18 - Chirurgia GeneraleRegimenOncologyCamptothecinFemaleEpidermal growth factor receptor Oxaliplatin Vascular endothelial growth factorColorectal Neoplasmsbusinessmedicine.drugClinical Colorectal Cancer
researchProduct

Proteinase-3 mRNA expressed by glomerular epithelial cells correlates with crescent formation in Wegener's granulomatosis

2000

Proteinase-3 mRNA expressed by glomerular epithelial cells correlates with crescent formation in Wegener's granulomatosis. Background Wegener's granulomatosis (WG) is characterized by systemic vasculitis with crescentic glomerulonephritis (CGN) and circulating autoantibodies directed against neutrophil cytoplasmic antigens (ANCA). Proteinase 3 (PR-3), a neutral serine proteinase in neutrophils implicated in the growth control of myeloid cells, has been identified as the target antigen for ANCA in WG. Since the kidneys are frequently involved in WG, we studied the in situ expression of PR-3 by renal parenchymal cells. Methods We assessed the expression of PR-3 in kidney biopsies of 15 patien…

AdultMalePathologymedicine.medical_specialtyBiopsyMyeloblastinKidney GlomerulusIn situ hybridizationBiologyurologic and male genital diseasesKidneyvasculitisAntigenProteinase 3medicineRapidly progressive glomerulonephritisHumanscrescent glomerulonephritisNorthern blotRNA Messengerrapidly progressive glomerulonephritisCells CulturedAgedKidneyANCAurogenital systemSerine EndopeptidasesGranulomatosis with PolyangiitisEpithelial CellsMiddle Agedmedicine.diseasekidney parenchymal cellsmedicine.anatomical_structureKidney TubulesNephrologyImmunohistochemistryFemaleSystemic vasculitisKidney International
researchProduct

Intravascular papillary endothelial hyperplasia: report of 4 cases with immunohistochemical findings.

2008

Intravascular papillary endothelial hyperplasia (IPEH) is a benign endothelial proliferation, usually intravascular, that may mimic angiosarcoma. In this report, four new cases of IPEH involving the oral region are described. The affected sites were the lower lip, labial comissure and the submandibular region. After clinical evaluation, the complete removal of the lesions showed a circumscribed and soft mass. Histologically, the major feature was a reactive proliferation of endothelial cells composed of small papillary structures with hypocellular and hyalinized cores arising in an organized thrombus. Immunohistochemical staining for CD34 was strongly positive in endothelial cells. Vimentin…

AdultMalePathologymedicine.medical_specialtyProliferative indexEndotheliumCD34VimentinmedicineHumansAngiosarcomaGeneral DentistryAgedHyperplasiabiologybusiness.industryHyperplasiaMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseImmunohistochemistrymedicine.anatomical_structureOtorhinolaryngologyIntravascular papillary endothelial hyperplasiaUNESCO::CIENCIAS MÉDICASbiology.proteinImmunohistochemistrySurgeryFemaleEndothelium VascularbusinessMouth DiseasesMedicina oral, patologia oral y cirugia bucal
researchProduct